CCL2 and COVID-19: The CCL2–monocyte link has indeed been pointed out as a putative mechanistic target for treating COVID‐19 and acute respiratory distress syndrome39 and could explain, at least in part, the beneficial effects of S1P ligands as a treatment for severe forms of COVID‐19.14